Literature DB >> 12363384

Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics.

Mohammad M Khan1, Denise R Evans, Vijayasudha Gunna, Russell E Scheffer, Vinay V Parikh, Sahebarao P Mahadik.   

Abstract

Abnormal membrane phospholipid essential polyunsaturated fatty acid (EPUFA) metabolism (i.e., reduced incorporation into phospholipids and increased breakdown) has been suggested to contribute to the etiopathophysiology of schizophrenia. However, most of the published studies have reported changes in the levels of membrane EPUFA in chronic medicated patients or in drug-naive patients long after onset of illness (1-2 years). Since the EPUFA metabolism can be altered by years of untreated illness or differentially altered by various antipsychotics, the significance of EPUFA membrane status to schizophrenia psychopathophysiology is unclear. We report the erythrocyte membrane EPUFA levels in drug-naive patients within +/- 4.5 days of onset of psychosis from an Army Medical Center, and in patients treated years with antipsychotics from a Veterans Affairs Medical Center. The levels of plasma lipid peroxides (TBARS, thiobarbituric acid reactive substances), products of damaged EPUFAs, were also determined. The levels of EPUFAs, particularly arachidonic acid (AA) and docosahexaenoic acid (DHA) were significantly lower (P < 0.001) in drug-naive patients at the onset of psychosis compared to matched normal controls. These lower EPUFA levels were associated with significantly higher levels of TBARS in patients (P < 0.001). The levels of AA and DHA were also lower (P < 0.001) and TBARS higher in chronic medicated patients than normal controls. However, the EPUFA levels were higher in chronic medicated patients than drug-naive first-episode patients. These data indicate that lower membrane AA and DHA most likely predate the illness and probably contribute to the onset of illness, and furthermore treatment with some antipsychotics may increase the levels of EPUFAs. The lipid peroxidation data suggest that possible increased oxidative stress, either as a part of the illness and/or its treatment with antipsychotics, may be one of the mechanisms of reduced membrane EPUFAs. These findings may have a significant impact on improving strategies for supplementation of EPUFAs and antioxidants to improve the outcome of schizophrenia. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12363384     DOI: 10.1016/s0920-9964(01)00334-6

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  60 in total

Review 1.  Role of perinatal long-chain omega-3 fatty acids in cortical circuit maturation: Mechanisms and implications for psychopathology.

Authors:  Robert K McNamara; Jennifer J Vannest; Christina J Valentine
Journal:  World J Psychiatry       Date:  2015-03-22

2.  First-episode bipolar disorder is associated with erythrocyte membrane docosahexaenoic acid deficits: Dissociation from clinical response to lithium or quetiapine.

Authors:  Robert K McNamara; Ronald Jandacek; Patrick Tso; Thomas J Blom; Jeffrey A Welge; Jeffrey R Strawn; Caleb M Adler; Melissa P DelBello; Stephen M Strakowski
Journal:  Psychiatry Res       Date:  2015-10-09       Impact factor: 3.222

3.  Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls.

Authors:  Suzanne Medema; Roel J T Mocking; Maarten W J Koeter; Frédéric M Vaz; Carin Meijer; Lieuwe de Haan; Nico J M van Beveren; René Kahn; Lieuwe de Haan; Jim van Os; Durk Wiersma; Richard Bruggeman; Wiepke Cahn; Carin Meijer; Inez Myin-Germeys
Journal:  Schizophr Bull       Date:  2015-09-18       Impact factor: 9.306

4.  Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: evidence for augmented biosynthesis.

Authors:  Robert K McNamara; Jessica A Able; Ronald Jandacek; Therese Rider; Patrick Tso
Journal:  Schizophr Res       Date:  2008-11-07       Impact factor: 4.939

Review 5.  Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia.

Authors:  Mohammad M Khan
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

6.  Early psychosis research at Orygen, The National Centre of Excellence in Youth Mental Health.

Authors:  S M Cotton; K M Filia; A Ratheesh; K Pennell; S Goldstone; P D McGorry
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-01       Impact factor: 4.328

7.  Phospholipid profile in the postmortem hippocampus of patients with schizophrenia and bipolar disorder: no changes in docosahexaenoic acid species.

Authors:  Kei Hamazaki; Kwang H Choi; Hee-Yong Kim
Journal:  J Psychiatr Res       Date:  2010-01-06       Impact factor: 4.791

8.  The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison.

Authors:  Anna Dietrich-Muszalska; Justyna Kopka; Anna Kwiatkowska
Journal:  Neurochem Res       Date:  2013-04-26       Impact factor: 3.996

9.  Diffusion Imaging of White Matter In Schizophrenia: Progress and Future Directions.

Authors:  Katherine H Karlsgodt
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-05

10.  A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia.

Authors:  Om Prakash Singh; Indranil Chakraborty; Anindya Dasgupta; Subinay Datta
Journal:  Indian J Psychiatry       Date:  2008-07       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.